NeuroPace has developed the RNS® System, the only FDA-approved device that utilizes responsive neurostimulation to monitor and respond to abnormal brain activity in patients with drug-resistant focal epilepsy. This technology provides personalized treatment by delivering targeted stimulation based on a patient's unique seizure patterns, significantly reducing seizure frequency and improving quality of life.
Funding
$9.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Patients with drug-resistant focal epilepsy often experience uncontrolled seizures despite trying multiple medications. Current treatment options may not provide sufficient seizure control, leading to a reduced quality of life and potential safety risks.
Solution
NeuroPace's RNS System is an FDA-approved, closed-loop neuromodulation device designed to treat drug-resistant focal epilepsy. The system continuously monitors a patient's unique brain activity via implanted electrodes and responds in real-time by delivering targeted electrical stimulation to disrupt abnormal patterns before they escalate into seizures. This personalized, responsive therapy aims to reduce seizure frequency and improve overall well-being by adapting to the individual's specific neurological needs. The RNS System also provides clinicians with access to continuous EEG data, offering insights into seizure trends and triggers to optimize treatment strategies.
Target Audience
The primary target audience includes adult patients (18 years or older) with drug-resistant focal epilepsy who have not achieved adequate seizure control with medication, as well as epileptologists, neurosurgeons, and neurologists specializing in epilepsy treatment.
Features
- Real-time, responsive neurostimulation triggered by detection of patient-specific seizure patterns
- Closed-loop system that continuously monitors and responds to brain activity
- Personalized therapy that adapts to individual neurological needs
- Implantable neurostimulator with chronic EEG monitoring capabilities
- Clinician access to continuous EEG data for insights into seizure trends and triggers
- Remote monitoring and programming adjustments
- MRI conditional